Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
LONDON, August 2, 2013
LONDON, August 2, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Thursday, August 1, 2013, shares in biotechnology companies ended mostly
higher, tracking the broader market which also finished high on the back of
positive US economic statistics. The major movers in the industry included
MannKind Corporation (NASDAQ: MNKD), Galena Biopharma Inc. (NASDAQ: GALE),
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), and Novavax Inc. (NASDAQ: NVAX).
All these companies are tracked by AAAResearchReports.com. Free technical
research on MNKD, GALE, ARIA, and NVAX can be downloaded upon sign up at:
Shares in MannKind Corporation rallied on Thursday, extending their gains from
previous trading sessions. The company's shares hit a 52-week high of $8.25
before finishing the day 4.15% higher at $8.03. A total of 11.33 million
shares were traded, which is above the daily average volume of 6.32 million.
The stock has gained 10.45% in the last three trading sessions and 18.26% in
the last one month as compared to a gain of 1.28% and 5.69% in the S&P 500
during the respective periods. Sign up and read the complimentary report on
Galena Biopharma Inc.'s stock surged on Thursday, finishing at $2.09, up 7.18%
from its previous closing price. The company's shares fluctuated between $1.95
and $2.10. A total of 2.87 million shares were traded, which is above the
daily average volume of 1.86 million. The stock has gained 17.42% in the last
three sessions, outperforming the S&P 500. Further, the stock is trading above
its 50-day and 200-day moving averages. The free report on GALE can be
downloaded by signing up now at:
Shares in Ariad Pharmaceuticals Inc. moved higher on Thursday, tracking gains
in the broader market. The company's shares traded between $18.57 and $19.04
before ending the session 2.10% higher at $18.97. A total of 1.38 million
shares were traded, which is below the daily average volume of 2.17 million.
The company's shares have advanced 3.21% in the last three sessions,
outperforming the S&P 500. However, in the last one month, the stock has
underperformed the broader market, falling by 2.87% as compared to a gain of
5.69% in the S&P 500. A free report on ARIA can be accessed by registering at:
Novavax Inc.'s stock edged lower on Thursday even as the broader market posted
significant gains. The company's shares oscillated between $2.63 and $2.74
before finishing the day 0.37% lower at $2.68. A total of 2.03 million shares
were traded, which is above the daily average volume of 1.78 million. Despite
Thursday's pullback, the company's shares have gained 6.77% in the last three
trading sessions, outperforming the S&P 500. Moreover, the stock is currently
trading near its 52-week high of $2.78 and above its 50-day and 200-day moving
averages. Register with AAA Research Reports and download research on NVAX for
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by a CFA. However, we are only human and are prone to
make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
SOURCE AAA Research Reports
Contact: + 1 (646) 396-9126
Press spacebar to pause and continue. Press esc to stop.